Dr. Samuel B. Wolf, D.O.
OB-GYN (Obstetrics & Gynecology) (Obstetrics & Gynecology Physician)
103 E 23rd St
Panama City, FL 32405
Who else practices at this address →
Bay County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 96
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Obstetrics & Gynecology Physician primary
FL license OS8825
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Map: OB-GYN (Obstetrics & Gynecology) per capita by county →
Where they work
Hospitals
- HCA Florida Gulf Coast Hospital Panama City, FL
Medical groups
- Florida Woman Care LLC (613 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 96
- Services billed
- 329
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 82 | 64 |
| Screening mammography | 33 | 33 |
| Screening 3d breast mammography | 32 | 32 |
| New patient office or other outpatient visit, 45-59 minutes | 27 | 27 |
| Established patient office or other outpatient visit, 20-29 minutes | 22 | 21 |
| Cervical or vaginal cancer screening; pelvic and clinical breast examination | 19 | 19 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Estradiol Other prescribers in Panama City, FL | 98 |
| Ciprofloxacin Hcl Other prescribers in Panama City, FL | 17 |
| Gemtesa (vibegron) Other prescribers in Panama City, FL | 17 |
| Fluconazole Other prescribers in Panama City, FL | 14 |
| Premarin (estrogens, conjugated) Other prescribers in Panama City, FL | 13 |
| Oxycodone-Acetaminophen (oxycodone hcl/acetaminophen) Other prescribers in Panama City, FL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 6 companies reported 6 payments worth $106 in total to this clinician.
| Intuitive Surgical, Inc. | $27.46 |
|---|---|
| Astellas Pharma US Inc | $18.18 |
| Medtronic, Inc. | $16.34 |
| Exeltis, USA Inc. | $16.29 |
| Boston Scientific Corporation | $14.70 |
| Bayer HealthCare Pharmaceuticals Inc. | $13.47 |
| Food and Beverage | $106 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 8 industry-funded studies in 2025, from 5 companies. The companies reported $253,326 in research payments for these studies, mostly to the institutions running them.
- A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis
Sumitomo Pharma America, Inc. · Recruiting · NCT05862272 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A phase 3 study to investigate the safety tolerability and immunogenicity of revaccinating pregnant participants during subsequent pregnancies and persistence of immunity of a single dose of a bivalent respiratory syn…
Pfizer Inc. - Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy
Sumitomo Pharma America, Inc. · Completed · NCT04756037 - Informed Choice - Compass
Exact Sciences Corporation · Terminated · NCT05246839 - Study name not reported
Organon Llc - Informed Choice Intervention for Colorectal Cancer Screening: COMPASS
Exact Sciences Corporation - A phase 3 randomized placebocontrolled doubleblinded trial to evaluate the safety tolerability and immunogenicity of a multivalent group b streptococcus vaccine in healthy pregnant women and their infants
Pfizer Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.